DMRA

Damora Therapeutics Inc

20.75

Sep 28 • 3:59 PM ET +0.09 (0.44%)

20.75

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: RYTM KYMR BMRN CRNX INCY KRYS VKTX AXSM MDGL NBIX

| Held by: IWM XBI VTWO IWO VXF SCHA IWN ITOT VTWG VFMO

Index	RUT
Market Cap	1.28B
Enterprise Value	870.51M
Income	-262.83M
Sales	0.00M
Book/sh	6.25
Cash/sh	8.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Oct 29, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.32
P/C	2.37
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	19.73
Current Ratio	19.73
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-124.78
EPS next Y	-2.08
EPS next Q	-0.47
EPS this Y	49.63%
EPS next Y	-3.65%
EPS next 5Y	13.54%
EPS past 3/5Y	-36.14% -34.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	-850.33%
Sales Y/Y TTM	-
EPS Q/Q	80.38%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	0.00% -

Insider Own	22.06%
Insider Trans	0.09%
Inst Own	87.80%
Inst Trans	17.49%
ROA	-94.32%
ROE	-100.00%
ROIC	-50.93%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.55%
SMA50	-26.52%
SMA200	-21.17%
Trades

Shs Outstand	61.73M
Shs Float	48.13M
Short Float	9.83%
Short Ratio	7.07
Short Interest	4.73M
52W High	38.33 -45.86%
52W Low	3.50 492.86%
Volatility	7.11% 7.63%
ATR (14)	1.84
RSI (14)	28.71
Beta	1.41
Rel Volume	0.77
Avg Volume	669.71K
Volume	514,914

Perf Week	-9.19%
Perf Month	-32.19%
Perf Quarter	-14.29%
Perf Half Y	-18.63%
Perf YTD	-9.82%
Perf Year	370.52%
Perf 3Y	14.48%
Perf 5Y	-77.38%
Perf 10Y	-
Recom	1.00
Target Price	46.89
Prev Close	20.66
Price	20.75
Change %	0.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-26	Initiated	Jefferies	Buy	$50
Jun-11-26	Initiated	H.C. Wainwright	Buy	$45
Jun-08-26	Initiated	TD Cowen	Buy
May-28-26	Initiated	Wedbush	Outperform	$35
Apr-24-26	Initiated	RBC Capital Mkts	Outperform	$40
Mar-25-26	Initiated	Evercore ISI	Outperform	$46
Feb-17-26	Initiated	UBS	Buy	$45
Jan-07-26	Initiated	Leerink Partners	Outperform	$46
Dec-01-25	Initiated	Guggenheim	Buy	$32
Apr-26-21	Resumed	Credit Suisse	Outperform	$12
Nov-23-20	Initiated	SVB Leerink	Outperform	$27
Nov-23-20	Initiated	Credit Suisse	Outperform	$29
Nov-23-20	Initiated	BofA Securities	Buy	$21

Show Previous Ratings

Sep-03-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-10-26 04:05PM	Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-26 08:00AM	Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis (GlobeNewswire)
Aug-03-26 04:01PM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.11%
Jul-17-26 08:00AM	Damora Announces Redomestication from Delaware to Cayman Islands (GlobeNewswire)
04:01PM	Loading…
Jul-01-26 04:01PM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.67%
Jun-01-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-12-26 04:05PM	Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.21%
May-01-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-23-26 08:00AM	Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors (GlobeNewswire) +27.07%
Mar-19-26 04:10PM	Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -9.22% -5.52%
Mar-09-26 08:00AM	Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders (GlobeNewswire)
Mar-04-26 08:00AM	Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.70%
Mar-02-26 08:00AM	Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Feb-12-26 04:01PM	Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million (GlobeNewswire) +37.75%
Feb-10-26 10:42PM	Galecto Announces Pricing of $275 Million Underwritten Public Offering (GlobeNewswire) -10.33%
04:04PM	Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (GlobeNewswire)
Jan-12-26 08:00AM	Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones (GlobeNewswire) +6.44%
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
Jan-06-26 08:00AM	Galecto Announces Key Additions to Leadership Team (GlobeNewswire)
Dec-16-25 05:00PM	Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.06% -12.23%
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-10-25 04:05PM	This Penny Stock Just Quadrupled. Should You Buy It Now? (Barchart) +248.48% +36.70%
07:00AM	Galecto Announces Acquisition of Damora Therapeutics (GlobeNewswire)
Nov-06-25 04:30PM	Galecto Reports Third Quarter 2025 Operating and Financial Results (GlobeNewswire) -14.95%
Nov-03-25 09:00AM	Galecto to Highlight GB3226 Program at ASH 2025 (GlobeNewswire) -8.47%
Oct-07-25 04:43PM	This Penny Stock Just Jumped 750%. Can It Retain These Gains for the Long Term? (Barchart) +383.02% -40.57%
Aug-05-25 04:15PM	Galecto Reports Second Quarter 2025 Operating and Financial Results (GlobeNewswire)
May-08-25 04:30PM	Galecto Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire) +5.15%
04:45PM	Loading…
Mar-19-25 04:45PM	Galecto Reports Full-Year 2024 Financial Results (GlobeNewswire)
Feb-06-25 08:00AM	Galecto to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 09:55AM	Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-01-24 08:30AM	Galecto Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-18-24 08:15AM	Galecto price target raised to $10 from $9 at Oppenheimer (TipRanks) +5.79%
Oct-15-24 08:30AM	Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler (GlobeNewswire)
Oct-07-24 08:45AM	Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines (GlobeNewswire) -27.53%
Aug-28-24 09:00AM	Galecto Announces Reverse Stock Split (GlobeNewswire) -6.59%
Aug-12-24 10:53PM	GLTO Stock Earnings: Galecto Beats EPS for Q2 2024 (InvestorPlace) +6.26%
May-03-24 10:54AM	GLTO Stock Earnings: Galecto Beats EPS for Q1 2024 (InvestorPlace)
May-01-24 04:01PM	Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab (GlobeNewswire) +5.43%
Mar-15-24 01:53PM	GLTO Stock Earnings: Galecto Beats EPS for Q4 2023 (InvestorPlace) +5.30%
Feb-14-24 12:00PM	Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +11.93%
Jan-09-24 04:57PM	What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock (Zacks)
Dec-22-23 06:52AM	Galecto posts myelofibrosis data as search for savior continues, investors shrug (FierceBiotech.com)
Dec-21-23 04:05PM	Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis (GlobeNewswire)
Oct-23-23 08:00AM	Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial (GlobeNewswire)
Sep-28-23 09:49AM	Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Sep-27-23 05:08AM	Galecto lays off 70%, hunts for 'strategic alternatives' in wake of fibrosis drug fail (FierceBiotech.com) +22.24%
Sep-26-23 04:01PM	Galecto Announces Plans to Explore Strategic Alternatives (GlobeNewswire)
Aug-31-23 11:00AM	Galecto to Present at Investor Conferences in September (GlobeNewswire)
Aug-17-23 07:01PM	OrbiMed Advisors LLC Reduces Stake in Galecto Inc (GuruFocus.com) -7.34%
08:58AM	Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More (Zacks)
Aug-16-23 07:46AM	Galecto (GLTO) Down 71% as Lung Disease Candidate Fails (Zacks)
Aug-15-23 07:35AM	Galecto to discontinue development of lung disease treatment (Reuters) -71.22%
07:30AM	Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-31-23 04:05PM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire) -9.09%
Jul-27-23 11:02PM	ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc (GuruFocus.com)
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +29.79%
Jun-20-23 08:58AM	Galecto Set to Join Russell Microcap® Index (GlobeNewswire)
May-30-23 08:00AM	Galecto to Present at the Upcoming Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 08:30AM	Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-20-23 08:54AM	Companies Like Galecto (NASDAQ:GLTO) Could Be Quite Risky (Simply Wall St.)
May-17-23 04:01PM	Galecto to Present Poster at Upcoming ATS 2023 International Conference (GlobeNewswire) +5.86%
Apr-28-23 08:00AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-13-23 08:30AM	Galecto to Present Two Posters at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 07:00AM	Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022 (GlobeNewswire) -8.13%
Mar-02-23 04:05PM	Galecto to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Galecto to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire) +5.65%
Dec-11-22 07:36AM	Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-07-22 04:05PM	Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-22 09:55AM	Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 12:00PM	All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy (Zacks)
Nov-08-22 09:15AM	Galecto Reports Third Quarter Operating and Financial Results (GlobeNewswire) -7.35%
06:00AM	Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients (GlobeNewswire)
Nov-03-22 08:00AM	Galecto to Participate in Jefferies London Healthcare Conference (GlobeNewswire) +20.01%
Oct-31-22 08:00AM	Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLDs The Liver Meeting® 2022 (GlobeNewswire) +6.35%
Oct-19-22 08:00AM	Galectos Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute (GlobeNewswire)
Oct-17-22 06:00AM	Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022 (GlobeNewswire)
Sep-29-22 11:17AM	Galecto's Myelofibrosis Candidate Reduces Bone Marrow Fibrosis (Benzinga) -22.08%
06:00AM	GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target (GlobeNewswire)
Sep-06-22 08:30AM	Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-29-22 08:30AM	Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal (GlobeNewswire)
Jul-29-22 09:00AM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire)
Jul-03-22 08:17AM	Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely? (Simply Wall St.)
Jun-16-22 08:00AM	Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC (GlobeNewswire)
May-31-22 08:30AM	Galecto to Participate at Jefferies Healthcare Conference (GlobeNewswire)
May-26-22 08:30AM	Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting (GlobeNewswire)
May-02-22 08:30AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-29-22 08:57AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-26-22 08:30AM	Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF (GlobeNewswire) -7.94%
Mar-29-22 08:30AM	Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (GlobeNewswire)
Mar-25-22 10:25AM	UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health (Zacks)
Mar-15-22 11:10AM	Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow? (Zacks)
Mar-10-22 11:05AM	Here's Why You Should Retain Community Health (CYH) Stock (Zacks)
Mar-09-22 10:49AM	Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View (Zacks) +7.49%
Mar-04-22 10:00AM	Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-17-22 05:00PM	Galecto Reports Financial Results for the Year Ended December 31, 2021 (GlobeNewswire) -5.48% -5.29%
Feb-07-22 08:00AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-27-22 07:00AM	Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care (GlobeNewswire)

Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Waltham, MA.

Senior VPMr. Garrett Winslow Esq.

CEOMs. Jennifer A. Jarrett M.B.A.

Co-FounderMr. Ulf J. Nilsson Ph.D.

Ph.D.Dr. Hakon Leffler M.D.

FRCPProf. Tariq Sethi B.Sc.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jarrett Jennifer	Director, President and CEO	Sep 25 '26	Buy	20.23	12,500	252,875	512,500	Sep 28 07:00 AM
Firmani Lori	Officer	Aug 05 '26	Proposed Sale	31.10	1,800	55,980		Aug 06 11:34 AM
Winslow Garrett	General Counsel	Jul 06 '26	Sale	29.98	245	7,345	2,289	Jul 07 08:00 PM
Firmani Lori	Officer	Jun 22 '26	Proposed Sale	25.36	7,615	193,140		Jun 22 02:27 PM
Bruno Julianne	Director	Feb 09 '26	Option Exercise	0.00	129,000	0	137,032	Feb 12 06:05 AM
Fairmount Funds Management LLC	Director	Feb 09 '26	Option Exercise	0.00	8,713,000	0	5,809,000	Feb 12 06:03 AM
Schambye Hans T.	Chief Executive Officer	Jan 02 '26	Sale	21.38	700	14,966	4,682	Jan 06 04:30 PM
Winslow Garrett	General Counsel	Jan 02 '26	Sale	21.38	255	5,452	1,854	Jan 06 04:30 PM
Firmani Lori	Chief Financial Officer	Jan 02 '26	Sale	21.41	135	2,890	931	Jan 06 04:30 PM

Open in Screener

FTHY

First Trust High Yield Opportunities 2027 Term Fund

12.85

Sep 28 • 3:59 PM ET -0.15 (-1.15%)

12.85

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Financial Closed-End Fund - Debt USA Small NYSE

FTHY First Trust High Yield Opportunities 2027 Term Fund daily Stock Chart

Peers: FCT PDO HYT GHY PTY

| Held by: YYY CEFZ

Index	-
Market Cap	472.53M
Enterprise Value	-
Income	-
Sales	-
Book/sh	-
Cash/sh	-
Dividend Est.	-
Dividend TTM	1.50 (11.67%)
Dividend Ex-Date	Oct 01, 2026
Dividend Gr. 3/5Y	-2.01% 20.31%
Payout	-
Employees	-
IPO	Jun 26, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	-
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	87.03%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.71%
SMA50	-3.61%
SMA200	-5.73%
Trades

Shs Outstand	36.77M
Shs Float	36.58M
Short Float	0.23%
Short Ratio	0.86
Short Interest	0.09M
52W High	14.64 -12.20%
52W Low	12.87 -0.16%
Volatility	0.90% 0.77%
ATR (14)	0.11
RSI (14)	31.05
Beta	0.65
Rel Volume	1.73
Avg Volume	98.81K
Volume	171,372

Perf Week	-1.38%
Perf Month	-4.46%
Perf Quarter	-6.41%
Perf Half Y	-4.03%
Perf YTD	-8.67%
Perf Year	-11.56%
Perf 3Y	-3.96%
Perf 5Y	-37.33%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	13.00
Price	12.85
Change %	-1.15%

Sep-21-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for October (Business Wire)
Aug-20-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for September (Business Wire)
Aug-03-26 07:21AM	FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND's Dividend Analysis (GuruFocus.com)
Jul-20-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for August (Business Wire)
Jun-18-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for July (Business Wire)
04:10PM	Loading…
May-20-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for June (Business Wire)
Apr-20-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for May (Business Wire)
Mar-19-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for April (Business Wire)
Feb-19-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for March (Business Wire)
Jan-20-26 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for February (Business Wire)
Dec-18-25 04:12PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for January (Business Wire)
Nov-20-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for December (Business Wire)
Oct-20-25 08:59PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for November (Business Wire)
Sep-18-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for October (Business Wire)
Aug-20-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for September (Business Wire)
04:10PM	Loading…
Jul-21-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for August (Business Wire)
Jun-18-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for July (Business Wire)
May-20-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for June (Business Wire)
Apr-28-25 03:54PM	2 CEFs That Can Benefit From Fed Keeping Its Target Rate Higher (Seeking Alpha)
Apr-21-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for May (Business Wire)
Mar-20-25 04:18PM	First Trust High Yield Opportunities 2027 Term Fund declares $0.125 dividend (SeekingAlpha)
04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for April (Business Wire)
Feb-20-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for March (Business Wire)
Jan-21-25 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for February (Business Wire)
Dec-19-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for January (Business Wire)
Nov-20-24 05:50PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for December (Business Wire)
Oct-21-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Decreases its Monthly Common Share Distribution to $0.125 Per Share for November (Business Wire)
Sep-19-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for October (Business Wire)
Aug-20-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for September (Business Wire)
Jul-22-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for August (Business Wire)
04:10PM	Loading…
Jun-20-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for July (Business Wire)
May-20-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for June (Business Wire)
Apr-22-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for May (Business Wire)
Mar-20-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for April (Business Wire)
Feb-20-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for March (Business Wire)
Jan-22-24 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for February (Business Wire)
Dec-20-23 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for January (Business Wire)
Nov-20-23 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for December (Business Wire)
Nov-13-23 04:10PM	First Trust Advisors L.P. Announces Portfolio Manager Update for First Trust Senior Floating Rate Income Fund II and First Trust High Yield Opportunities 2027 Term Fund (Business Wire)
Oct-23-23 04:15PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for November (Business Wire)
Sep-20-23 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for October (Business Wire)
Aug-21-23 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for September (Business Wire)
Jul-20-23 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for August (Business Wire)
Jun-20-23 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for July (Business Wire)
May-22-23 04:15PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for June (Business Wire)
Apr-20-23 04:15PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.13 Per Share for May (Business Wire)
Mar-20-23 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Increases its Monthly Common Share Distribution to $0.13 Per Share for April (Business Wire)
Feb-21-23 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1269 Per Share for March (Business Wire)
Jan-23-23 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1269 Per Share for February (Business Wire)
Dec-20-22 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1269 Per Share for January (Business Wire)
Nov-21-22 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1269 Per Share for December (Business Wire)
Nov-02-22 04:15PM	First Trust Advisors L.P. Announces Portfolio Manager Update for First Trust Senior Floating Rate Income Fund II and First Trust High Yield Opportunities 2027 Term Fund (Business Wire)
Oct-20-22 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1269 Per Share for November (Business Wire)
Sep-20-22 04:05PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1269 Per Share for October (Business Wire)
Aug-22-22 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1269 Per Share for September (Business Wire)
Jul-20-22 04:15PM	First Trust High Yield Opportunities 2027 Term Fund Decreases its Monthly Common Share Distribution to $0.1269 Per Share for August (Business Wire)
Jun-21-22 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1344 Per Share for July (Business Wire)
May-23-22 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1344 Per Share for June (Business Wire)
Apr-20-22 04:15PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1344 Per Share for May (Business Wire)
Mar-21-22 04:15PM	First Trust High Yield Opportunities 2027 Term Fund Decreases Its Monthly Common Share Distribution to $0.1344 Per Share for April (Business Wire)
Feb-17-22 04:48PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1494 Per Share for March (Business Wire)
Jan-20-22 04:15PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1494 Per Share for February (Business Wire)
Dec-20-21 04:30PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1494 Per Share for January (Business Wire)
Nov-22-21 04:10PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1494 Per Share for December (Business Wire)
Nov-01-21 04:10PM	First Trust Advisors L.P. Announces Portfolio Manager Update for First Trust Senior Floating Rate Income Fund II, First Trust Senior Floating Rate 2022 Target Term Fund and First Trust High Yield Opportunities 2027 Term Fund (Business Wire)
Oct-20-21 04:30PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1494 Per Share for November (Business Wire)
Sep-20-21 04:30PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1494 Per Share for October (Business Wire)
Aug-23-21 04:30PM	First Trust High Yield Opportunities 2027 Term Fund Increases its Monthly Common Share Distribution to $0.1494 Per Share for September (Business Wire)
Jul-20-21 04:30PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1194 Per Share for August (Business Wire)
Jun-21-21 04:27PM	First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.1194 Per Share for July (Business Wire)

First Trust High Yield Opportunities 2027 Term Fund is a diversified, closed-end management investment company that seeks current income. The Fund invests in high yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities determined by the Advisor to be of comparable quality.

CMTMr. Orlando Purpura C.F.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCGAREL DAVID	Officer-Investment Adviser	Sep 25 '26	Buy	12.92	10,000	129,247	24,000	Sep 28 10:50 AM
HOUSEY WILLIAM A JR	Officer of Advisor, Port. Mgr.	Sep 24 '26	Buy	12.90	5,000	64,500	21,841	Sep 25 11:33 AM
HOUSEY WILLIAM A JR	Officer of Advisor, Port. Mgr.	Sep 23 '26	Buy	12.95	5,241	67,864	16,841	Sep 24 12:26 PM

Open in Screener

DX

Dynex Capital Inc

11.33

Sep 28 • 3:59 PM ET -0.01 (-0.09%)

11.40

Aftermarket • 5:17 PM ET +0.07 (0.62%)

Real Estate REIT - Mortgage USA Mid NYSE

Peers: AGNC NLY RITM MFA RWT PMT BXMT STWD ARI KREF

| Held by: VTI IWM VXF IWN REM VTWO MORT SCHA KBWD SDIV

Index	RUT
Market Cap	2.81B
Enterprise Value	24.96B
Income	425.28M
Sales	895.58M
Book/sh	12.92
Cash/sh	2.45
Dividend Est.	2.04 (18.01%)
Dividend TTM	2.04 (18.01%)
Dividend Ex-Date	Sep 21, 2026
Dividend Gr. 3/5Y	8.63% 3.80%
Payout	80.98%
Employees	28
IPO	Feb 10, 1988

P/E	4.32
Forward P/E	7.06
PEG	0.30
P/S	3.14
P/B	0.88
P/C	4.63
P/FCF	11.88
EV/EBITDA	23.20
EV/Sales	27.87
Quick Ratio	0.06
Current Ratio	0.06
Debt/Eq	7.13
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	2.62
EPS next Y	1.61
EPS next Q	0.39
EPS this Y	65.32%
EPS next Y	8.24%
EPS next 5Y	23.16%
EPS past 3/5Y	-7.98% -18.63%
Sales past 3/5Y	- 18.10%
EPS Y/Y TTM	234.34%
Sales Y/Y TTM	136.45%
EPS Q/Q	653.65%
Sales Q/Q	170.93%
Earnings	Jul 20 BMO
EPS/Sales Surpr.	-1.32% -9.50%

Insider Own	0.80%
Insider Trans	0.23%
Inst Own	48.08%
Inst Trans	6.88%
ROA	2.31%
ROE	18.23%
ROIC	13.74%
Gross Margin	100.00%
Oper. Margin	120.13%
Profit Margin	47.49%
SMA20	-7.92%
SMA50	-10.61%
SMA200	-14.58%
Trades

Shs Outstand	248.17M
Shs Float	246.17M
Short Float	6.72%
Short Ratio	2.82
Short Interest	16.55M
52W High	14.93 -24.12%
52W Low	11.11 1.93%
Volatility	2.51% 1.70%
ATR (14)	0.24
RSI (14)	17.42
Beta	0.95
Rel Volume	1.39
Avg Volume	5.88M
Volume	8,145,004

Perf Week	-6.13%
Perf Month	-12.17%
Perf Quarter	-14.04%
Perf Half Y	-6.90%
Perf YTD	-19.13%
Perf Year	-6.36%
Perf 3Y	-2.25%
Perf 5Y	-30.69%
Perf 10Y	-45.28%
Recom	1.67
Target Price	14.75
Prev Close	11.34
Price	11.33
Change %	-0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-24	Initiated	Janney	Buy	$13.50
Apr-12-24	Initiated	Compass Point	Buy	$14.50
Dec-06-23	Initiated	UBS	Neutral	$12.50
Jan-09-23	Upgrade	Credit Suisse	Neutral → Outperform	$13.50 → $15.50
Jun-09-22	Upgrade	Keefe Bruyette	Mkt Perform → Outperform	$17 → $18.75
Dec-18-20	Downgrade	Keefe Bruyette	Outperform → Mkt Perform	$18
Nov-24-20	Initiated	BTIG Research	Buy
Jul-29-20	Upgrade	Ladenburg Thalmann	Neutral → Buy
Nov-26-19	Upgrade	Keefe Bruyette	Mkt Perform → Outperform	$15 → $17.50
May-02-19	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-27-19	Initiated	Nomura	Buy
Apr-28-16	Downgrade	Ladenburg Thalmann	Buy → Neutral
Feb-18-16	Reiterated	Maxim Group	Buy	$8.25 → $7.75
Aug-10-15	Reiterated	Maxim Group	Buy	$9.50 → $8.75
Jul-20-15	Upgrade	MLV & Co	Hold → Buy	$9.05 → $8.50
Jun-17-15	Downgrade	BofA/Merrill	Neutral → Underperform
Apr-30-15	Downgrade	Compass Point	Buy → Neutral	$10 → $8.50
May-09-14	Downgrade	MLV & Co	Buy → Hold
Sep-17-13	Initiated	MLV & Co	Buy	$9
Sep-16-13	Initiated	Compass Point	Buy	$9.50

Show Previous Ratings

Today 05:59AM	Sterling today: Pound edges higher as U.S. data tests dollar rally (Investing.com)
01:19AM	Dollar pinned at two-month high as bond rout extends, Fed rate hike bets rise (Investing.com)
Sep-27-26 09:43PM	Gold tumbles below $4,200 as oil, Fed hike bets weigh on bullion (Investing.com)
Sep-24-26 11:08PM	Yen jumps as Trump shows concern over its weakness, dollar halts daily win streak (Investing.com)
09:42PM	Gold on track for weekly loss as Fed hike bets rise, dollar weighs (Investing.com)
05:25PM	Loading…
Sep-22-26 05:25PM	Dynex Capital, Inc. Announces Pricing of Public Offering of Series D Fixed-Rate Cumulative Redeemable Preferred Stock (Business Wire)
Sep-21-26 07:05AM	Dynex Capital Inc's Dividend Analysis (GuruFocus.com)
Sep-14-26 06:24PM	Loonie holds near 12-day low as oil support fails to offset dollar strength (Investing.com)
06:47AM	Dollar at highest level in almost two weeks as Fed rate hike bets hit nearly 95% (Investing.com)
Sep-11-26 08:30AM	Dynex Capital, Inc. Declares Common and Preferred Stock Dividends (Business Wire)
Sep-01-26 10:54AM	Why JPM thinks rising bond yields wont derail the equity rally (Investing.com)
Aug-28-26 05:14PM	Canadian dollar slips as trade tensions, Fed outlook keep loonie under pressure (Investing.com)
Aug-27-26 10:28AM	Canadian dollar falls as traders weigh Fed outlook and U.S. dollar strength (Investing.com)
Aug-17-26 07:30AM	Why this Wall Street strategist says the "trade is long gold" (Investing.com)
Aug-11-26 04:15PM	Dynex Capital, Inc. Declares Monthly Common Stock Dividend of $0.17 (Business Wire)
11:05AM	Loading…
11:05AM	Cherry Hill Mortgages 29% Premium Deal: $9B Merger Opens Door to Bigger Upside Quarterly Update Report (Exec Edge)
Aug-01-26 12:35AM	Treasury sell-off shows Fed must reinforce inflation credibility, Musalem says (Investing.com)
Jul-21-26 08:30AM	Dynex Capital, Inc. Q2 2026 Earnings Call Summary (Moby)
Jul-20-26 05:00PM	Dynex Capital Inc (DX) Q2 2026 Earnings Call Highlights: Strong Economic Return and Strategic ... (GuruFocus.com)
08:13AM	Dynex Capital: Q2 Earnings Snapshot (Associated Press)
08:00AM	Dynex Capital, Inc. Announces Second Quarter 2026 Results (Business Wire)
Jul-13-26 04:15PM	Dynex Capital, Inc. Declares Monthly Common Stock Dividend of $0.17 (Business Wire)
Jul-06-26 04:15PM	Dynex Capital, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call (Business Wire)
Jul-01-26 01:59AM	Dollar firms as U.S. economic data, Warsh comments keep rate hike bets elevated (Investing.com)
Jun-30-26 01:52AM	Yen hits 40-year low amid intervention fears (Investing.com)
Jun-27-26 11:05PM	Is the U.S. dollar debasement trade dead? (Investing.com)
Jun-26-26 11:12AM	UBS turns more bullish on U.S. dollar, sees euro and yen weakening further (Investing.com)
08:41AM	Barclays warns summer volatility may persist as September Fed hike odds rise (Investing.com)
Jun-16-26 04:15PM	Dynex Capital Appoints Douglas Neal to Its Board of Directors (Business Wire)
Jun-13-26 01:50AM	Trump denies claims IRS lawsuit was used to create $1.8 billion fund (Investing.com)
07:04AM	Loading…
Jun-12-26 07:04AM	UBS cuts gold price forecasts on delayed Fed easing outlook (Investing.com)
Jun-11-26 04:15PM	Dynex Capital, Inc. Declares Common and Preferred Stock Dividends (Business Wire)
Jun-10-26 01:39AM	Dollar inches up in choppy session as traders parse Iran tensions, U.S. CPI data (Investing.com)
Jun-06-26 07:11PM	Goldman Sachs sees resilient U.S. economy, warns of slower consumer spending ahead (Investing.com)
05:08AM	Bitcoin rebounds above $60,000 after $1.6 billion liquidation-driven selloff (Investing.com)
Jun-04-26 08:03AM	This Stock Entices With A 15.9% Yield - But Is It Too Good To Be True? (Investor's Business Daily)
May-22-26 11:08PM	Goldman says pay attention to this important shift in FX market dynamics (Investing.com)
May-17-26 05:54AM	Fed hikes on the radar: Are EMs prepared? (Investing.com)
May-14-26 06:04PM	From war shock to fragile recovery: Why investors are still nervous? (Investing.com)
May-13-26 03:21PM	Senate confirms Kevin Warsh as Fed Chair amid rising inflation and policy shifts (Investing.com)
May-11-26 04:01PM	Dynex Capital, Inc. Declares Monthly Common Stock Dividend of $0.17 (Business Wire)
May-08-26 11:06AM	Japan spent billions to save Yen, but traders say currency crisis is far from over (Investing.com)
May-06-26 08:55AM	Sterling Today: Pound jumps as dollar sells off on Iran-Hormuz deal hopes (Investing.com)
Apr-23-26 09:44AM	US dollar faces uncertain path as markets shrug off war risks (Investing.com)
Apr-21-26 03:00AM	Dynex Capital Inc (DX) Q1 2026 Earnings Call Highlights: Navigating Market Volatility with ... (GuruFocus.com)
Apr-20-26 12:46PM	Dynex Capital, Inc. Q1 2026 Earnings Call Summary (Moby)
08:09AM	Dynex Capital: Q1 Earnings Snapshot (Associated Press)
07:59AM	Dynex Capital, Inc. Announces First Quarter 2026 Results (Business Wire)
Apr-13-26 04:01PM	Dynex Capital, Inc. Declares Monthly Common Stock Dividend of $0.17 (Business Wire)
03:54PM	Investors still skeptical about US dolLar strength amid geopolitical tensions (Investing.com)
Apr-07-26 09:18AM	TSX futures point lower with Trumps deadline fast approaching (Investing.com)
04:21AM	Sterling today: Pound weakens as White House deadline keeps dollar in demand (Investing.com)
Mar-31-26 04:01PM	Dynex Capital, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call (Business Wire)
Mar-30-26 10:54AM	Bonds emerging as hedge amid Middle East tensions, says Citadel Securities (Investing.com)
Mar-26-26 05:46AM	Futures dip, oil tops $100 as Iran reviews U.S. peace plan - whats moving markets (Investing.com)
Mar-20-26 11:07PM	Why is oil priced in dollars? (Investing.com)
Mar-11-26 04:00PM	Dynex Capital, Inc. Declares Common and Preferred Stock Dividends (Business Wire)
Mar-07-26 07:44AM	Energy shock risks pushing EUR/USD toward 1.13 floor, says Morgan Stanley (Investing.com)
Mar-06-26 02:04PM	Feds Hammack says rates should stay on hold for quite some time (Investing.com)
Mar-04-26 10:10AM	Cherry Hill Mortgage: 15.2% Dividend Yield Meets Growth Potential Quarterly Update Report (Exec Edge)
Mar-01-26 05:26AM	U.S. dollar seen strengthening as U.S.-Israel strikes intensify (Investing.com)
Feb-27-26 08:00AM	Dynex Capital, Inc. Announces CFO Transition (Business Wire)
Feb-21-26 04:00PM	Crypto holds steady amid inflation outlook and geopolitics risks, Nexo says (Investing.com)
08:22AM	IEEPA tariffs ruling: Here are the implications for Rates and FX markets (Investing.com)
Feb-11-26 04:01PM	Dynex Capital, Inc. Declares Monthly Common Stock Dividend of $0.17 (Business Wire)
Feb-10-26 07:23AM	Income Investors Chasing Dynex Capitals 14.3% Yield Should See These Numbers First (24/7 Wall St.)
Feb-09-26 09:44AM	IMFs Georgieva: dont see change in role of dollar anytime soon (Investing.com)
Feb-03-26 04:23PM	BTIG Flags Mortgage Policy Tailwind for Dynex Capital, Inc. (DX) (Insider Monkey)
07:53AM	Baird upgrades Palantir: Revenue and FCF too impressive (Investing.com)
Feb-01-26 04:30AM	How does a weaker dollar impact gold and Bitcoin? (Investing.com)
Jan-29-26 10:51AM	How Trump creates another run-hot influence on the economy (Investing.com)
Jan-28-26 10:27AM	US debt rating stable for now, says Fitch (Investing.com)
09:54AM	Fed keeps rates steady as expected, Powell refuses to discuss DoJ investigation (Investing.com)
Jan-27-26 08:15AM	Dynex Capital reports Q4 EPS $1.16 vs. $1.08 last year (TipRanks)
Jan-26-26 04:00PM	Dynex Capital Inc (DX) Q4 2025 Earnings Call Highlights: Record Economic Returns and Strategic ... (GuruFocus.com)
11:42AM	Dynex Capital Q4 Earnings Call Highlights (MarketBeat)
08:33AM	Dynex Capital: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Dynex Capital, Inc. Announces Fourth Quarter and Full Year 2025 Results (Business Wire)
12:01AM	Top Picks 2026- Dynex Capital Inc. DX (MoneyShow)
Jan-18-26 11:40PM	Asia FX muted amid Trump tariff row over Greenland; China Q4 GDP in focus (Investing.com)
Jan-16-26 04:09PM	Dynex Capital, Inc. Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call (Business Wire)
Jan-12-26 05:32PM	Dynex Capital, Inc. Declares Monthly Common Stock Dividend of $0.17 (Business Wire)
05:55AM	Sell America trade is back on as Powell subpoena rattles markets (Investing.com)
Dec-31-25 06:48AM	Dollar set for steepest annual decline in eight years (Investing.com)
Dec-27-25 01:03AM	Keefe Bruyette Reaffirms Bullish Agency REIT Stance, Raises Dynex (DX) Target (Insider Monkey)
Dec-24-25 09:42AM	TSX futures edge lower as liquidity thins ahead of Christmas break (Investing.com)
Dec-11-25 04:01PM	Dynex Capital, Inc. Declares Common and Preferred Stock Dividends (Business Wire)
Dec-01-25 02:36AM	This Real Estate Stock Is Yielding 14.6%! (Motley Fool)
Nov-24-25 06:00PM	Dollar set for wild ride in 2026 as year of pivots set to grip FX (Investing.com)
Nov-18-25 10:16AM	Dividend Investor Making $16,300 A Month Shares His Top 7 High-Yield Stocks 'Don't Let Anyone Tell You Dividend Investing Will Not Pay The Bills' (Benzinga)
Nov-11-25 11:17AM	Cherry-Sweet Yield Flags Valuation Upside at CHMI Quarterly Update Report (Exec Edge)
Nov-10-25 04:01PM	Dynex Capital, Inc. Declares Monthly Common Stock Dividend of $0.17 Per Common Share for November 2025 (Business Wire)
Oct-27-25 09:18AM	Truist sees several avenues of earnings growth for Booking Holdings (Investing.com)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
Oct-20-25 07:00PM	Dynex Capital Inc (DX) Q3 2025 Earnings Call Highlights: Strong Returns Amid Complex Market ... (GuruFocus.com)
10:29AM	Dynex Capital: Q3 Earnings Snapshot (Associated Press Finance)
09:15AM	Dynex Capital (DX) Lags Q3 Earnings Estimates (Zacks)
08:00AM	Dynex Capital, Inc. Announces Third Quarter 2025 Results (Business Wire)
Oct-17-25 09:17AM	What To Expect From Dynex Capital Inc (DX) Q3 2025 Earnings (GuruFocus.com)
Oct-16-25 08:02AM	This REIT Offers Sky-High Income, Along With A Few Caution Signs (Investor's Business Daily)

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Co-CEO & Chairman of the BoardMr. Byron L. Boston

Co-CEOMs. Smriti Laxman Popenoe C.F.A.

Chief Financial OfficerMr. Michael Sartori

Chief Operating OfficerMs. Meakin Bennett

Chief Investment OfficerMr. Terrence J. Connelly Jr.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Connelly Terrence John JR	Chief Investment Officer	Sep 25 '26	Buy	11.18	2,500	27,950	58,695	Sep 28 08:43 AM
Popenoe Smriti Laxman	Co-CEO and President	Feb 27 '26	Buy	12.19	2,000	24,380	550,626	Mar 30 05:33 PM

Open in Screener

ANIX

Anixa Biosciences Inc

2.79

Sep 28 • 3:59 PM ET +0.01 (0.36%)

2.85

Aftermarket • 5:00 PM ET +0.06 (2.15%)

Healthcare Biotechnology USA Micro NASD

ANIX Anixa Biosciences Inc daily Stock Chart

Peers: COYA CYPH INO LONA NRXS ATYR CGTX KLRS NRXP KALA

| Held by: VTI VXF IWC

Index	-
Market Cap	96.99M
Enterprise Value	82.03M
Income	-10.38M
Sales	0.00M
Book/sh	0.42
Cash/sh	0.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Oct 07, 1983

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.67
P/C	7.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.54
Current Ratio	8.54
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.31
EPS next Y	-0.32
EPS next Q	-0.08
EPS this Y	6.35%
EPS next Y	-1.08%
EPS next 5Y	0.29%
EPS past 3/5Y	9.05% 5.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.04%
Sales Y/Y TTM	-
EPS Q/Q	-9.64%
Sales Q/Q	-
Earnings	Jun 05
EPS/Sales Surpr.	14.71% -

Insider Own	5.55%
Insider Trans	8.06%
Inst Own	15.38%
Inst Trans	1.00%
ROA	-63.45%
ROE	-66.84%
ROIC	-71.11%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.67%
SMA50	-13.79%
SMA200	-7.92%
Trades

Shs Outstand	34.58M
Shs Float	32.78M
Short Float	3.22%
Short Ratio	3.37
Short Interest	1.05M
52W High	5.46 -48.87%
52W Low	2.32 20.26%
Volatility	5.52% 6.25%
ATR (14)	0.18
RSI (14)	40.41
Beta	0.47
Rel Volume	0.98
Avg Volume	312.77K
Volume	305,511

Perf Week	3.33%
Perf Month	-22.50%
Perf Quarter	-2.11%
Perf Half Y	9.41%
Perf YTD	-10.58%
Perf Year	-17.94%
Perf 3Y	-13.08%
Perf 5Y	-44.09%
Perf 10Y	-11.43%
Recom	1.00
Target Price	8.33
Prev Close	2.78
Price	2.79
Change %	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-25	Initiated	Maxim Group	Buy	$10
Dec-23-22	Initiated	Chardan Capital Markets	Buy	$8
Apr-12-21	Initiated	H.C. Wainwright	Buy	$11

Sep-21-26 08:45AM	Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 (PR Newswire)
Sep-16-26 09:15AM	Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board (PR Newswire)
Sep-09-26 08:35AM	Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV (PR Newswire)
Sep-03-26 08:00AM	Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 (PR Newswire)
Aug-24-26 08:55AM	Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy (PR Newswire)
08:45AM	Loading…
Aug-18-26 08:45AM	Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Jul-14-26 08:33AM	Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology (PR Newswire)
Jul-06-26 08:30AM	Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date (PR Newswire) -6.73%
Jun-30-26 06:35AM	Anixa Biosciences secures Korean patent for breast cancer vaccine (Pharmaceutical Business Review)
Jun-29-26 08:45AM	Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 (PR Newswire)
Jun-26-26 09:10AM	Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium (PR Newswire) +6.49%
Jun-11-26 09:05AM	Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium (PR Newswire) +5.53%
Jun-01-26 09:00AM	Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance (PR Newswire)
May-11-26 08:55AM	Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy (PR Newswire)
May-01-26 09:15AM	Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV (PR Newswire)
09:10AM	Loading…
Apr-29-26 09:10AM	Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Apr-22-26 08:45AM	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting (PR Newswire) +9.03%
Apr-09-26 09:05AM	Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 (PR Newswire)
Apr-07-26 08:55AM	Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 (PR Newswire)
Apr-06-26 09:10AM	Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs (PR Newswire)
Apr-01-26 08:50AM	Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing (PR Newswire) +5.43%
Mar-30-26 09:05AM	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (PR Newswire)
Mar-12-26 10:38AM	Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast (PR Newswire)
Mar-09-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Mar-02-26 09:10AM	Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress (PR Newswire)
Feb-23-26 08:55AM	Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat (PR Newswire)
Feb-10-26 03:50PM	Anixa Biosciences CEO Calls 2026 Pivotal as Breast Cancer Vaccine, Ovarian CAR-T Advance (MarketBeat)
Feb-09-26 08:00AM	Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation (PR Newswire)
07:31AM	EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues (Benzinga)
Feb-02-26 09:00AM	Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization (PR Newswire)
08:30AM	Loading…
Jan-27-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Dec-15-25 08:45AM	Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic (PR Newswire) -8.94%
Dec-10-25 09:00AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 (PR Newswire)
Nov-17-25 08:15AM	Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization (PR Newswire)
Nov-12-25 09:00AM	Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Nov-10-25 10:30AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 (PR Newswire)
Nov-05-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:55AM	Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic (PR Newswire)
Oct-23-25 08:45AM	Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference (PR Newswire)
Oct-20-25 08:25AM	Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Oct-17-25 12:00PM	Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice (Zacks) -6.82%
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire) +8.03%
Oct-07-25 08:30AM	Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial (PR Newswire) +26.46%
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
Sep-22-25 08:05AM	Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium (PR Newswire) +5.76%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
09:40AM	Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-09-25 06:45PM	3 Under-the-Radar Biotechs Under $5 That Could Soar 200% (MarketBeat)
Sep-08-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival (PR Newswire)
Sep-02-25 08:54AM	Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-25-25 09:13AM	Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-20-25 08:37AM	Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Aug-18-25 09:00AM	Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Aug-12-25 08:05AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology (PR Newswire)
Aug-08-25 09:15AM	Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference (PR Newswire)
Aug-04-25 08:45AM	Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial (PR Newswire) +8.31%
Jul-30-25 08:15AM	Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Jul-25-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-24-25 08:00AM	Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Jul-09-25 09:40AM	Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PR Newswire)
Jun-26-25 12:00PM	ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy? (Zacks)
Jun-23-25 09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
08:00AM	Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Jun-20-25 07:30AM	Anixa Biosciences to Host an Investor Webcast on June 26, 2025 (PR Newswire)
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire) +5.42%
Jun-10-25 12:00PM	What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? (Zacks)
07:00AM	Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage (PR Newswire)
Jun-09-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 (PR Newswire) +23.19%
Jun-05-25 12:00PM	All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy (Zacks)
09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
Jun-03-25 07:25AM	Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview (PR Newswire)
Jun-02-25 07:00AM	Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine (PR Newswire) +12.45%
May-19-25 08:00AM	Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones (PR Newswire)
May-12-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-30-25 08:00AM	Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th (PR Newswire)
Apr-14-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio (PR Newswire)
Apr-11-25 09:40AM	Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-10-25 09:58AM	ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up (Zacks)
Apr-09-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire) +13.03%
07:45AM	EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent (Benzinga)
Apr-01-25 08:00AM	Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th (PR Newswire)
Mar-25-25 08:00AM	Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines (PR Newswire)
07:51AM	EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines (Benzinga)
Mar-24-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine (PR Newswire)
07:46AM	EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine (Benzinga)
Mar-17-25 08:00AM	Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th (PR Newswire)
Mar-10-25 08:30AM	Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties (PR Newswire) -7.39%
Mar-03-25 08:00AM	Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th (PR Newswire) -9.84%
Feb-26-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-25-25 07:30AM	Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' 'America Reports' (PR Newswire)
Feb-24-25 08:00AM	Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer (PR Newswire) -6.49%
Feb-18-25 08:00AM	Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-14-25 07:00AM	Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview (PR Newswire)
Feb-11-25 08:30AM	Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum (PR Newswire)
Feb-04-25 08:30AM	Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention (PR Newswire) +6.07%
Jan-21-25 08:30AM	Anixa Biosciences CEO Provides Letter to Shareholders (PR Newswire) +16.60%
Dec-06-24 08:30AM	iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024 (ACCESS Newswire)
Dec-04-24 08:30AM	Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 (PR Newswire)
Nov-22-24 08:15AM	Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset (PR Newswire)

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

CEODr. Amit Kumar Ph.D.

MBAMr. Michael J. Catelani CPA

Chief Development Officer & Chair Breast Cancer Clinical Advisory BoardDr. Pamela D. Garzone Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KUMAR AMIT	Chief Executive Officer	Sep 24 '26	Buy	2.78	7,000	19,460	672,000	Sep 28 08:45 AM
Baskies Arnold M	Director	Sep 24 '26	Buy	2.76	5,000	13,800	140,572	Sep 28 08:30 AM
Titterton Lewis H jr	Director	Sep 23 '26	Buy	2.69	49,036	131,907	1,046,003	Sep 25 08:39 AM
KUMAR AMIT	Chief Executive Officer	Sep 10 '26	Buy	2.75	3,000	8,250	665,000	Sep 14 09:45 AM
Titterton Lewis H jr	Director	Sep 10 '26	Buy	2.73	10,000	27,300	996,967	Sep 14 09:15 AM
KUMAR AMIT	Chief Executive Officer	Sep 10 '26	Buy	2.76	5,000	13,800	662,000	Sep 11 08:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 31 '26	Buy	3.47	5,000	17,350	657,000	Aug 03 08:45 AM
Baskies Arnold M	Director	Jul 27 '26	Option Exercise	3.13	6,000	18,780	141,000	Jul 29 09:14 AM
KUMAR AMIT	Chief Executive Officer	Jul 27 '26	Buy	3.44	5,000	17,200	652,000	Jul 28 10:20 AM
KUMAR AMIT	Chief Executive Officer	Jul 27 '26	Buy	3.37	3,188	10,744	647,000	Jul 27 03:25 PM
KUMAR AMIT	Chief Executive Officer	Jul 24 '26	Buy	3.73	3,000	11,190	643,812	Jul 27 09:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 20 '26	Buy	3.46	5,000	17,300	640,812	Jul 21 10:23 AM
Titterton Lewis H jr	Director	Jul 20 '26	Buy	3.47	12,000	41,640	986,967	Jul 20 06:19 PM
Titterton Lewis H jr	Director	Jul 15 '26	Buy	3.28	2,797	9,174	974,967	Jul 16 09:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 10 '26	Buy	3.04	5,000	15,200	635,812	Jul 13 08:59 AM
Titterton Lewis H jr	Director	Jun 16 '26	Buy	2.64	2,836	7,487	972,170	Jun 17 11:21 AM
KUMAR AMIT	Chief Executive Officer	Jun 12 '26	Buy	2.50	21,000	52,500	630,812	Jun 16 09:00 AM
Baskies Arnold M	Director	Jan 28 '26	Buy	3.04	10,000	30,400	135,000	Jan 29 08:58 AM
Titterton Lewis H jr	Director	Dec 15 '25	Option Exercise	2.92	16,000	46,720	969,334	Dec 16 08:56 AM
KUMAR AMIT	Chief Executive Officer	Oct 30 '25	Option Exercise	2.92	200,000	584,000	779,925	Oct 31 09:13 AM

DMRA

Damora Therapeutics Inc

FTHY

First Trust High Yield Opportunities 2027 Term Fund

DX

Dynex Capital Inc

ANIX

Anixa Biosciences Inc

Upgrade your Finviz experience